Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte, Inc (Nasdaq: VCYT) will release its third quarter 2020 financial results after market close on November 2, 2020. The management will host a conference call at 4:30 p.m. ET the same day to discuss the results and provide a business update. A live webcast of the call will be accessible on the company's website, with a replay available for one year post-broadcast. Veracyte specializes in genomic diagnostics, offering tests for various cancers and diseases, aimed at improving patient care and diagnostic efficiency.